1 withdrawn. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Withdrawn 1 |
Follow Recurrent Follicular T-Cell Lymphoma: new trials by email Literature Review of Recurrent Follicular T-Cell Lymphoma trials Research Report on Recurrent Follicular T-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma Brentuximab Vedotin, Pembrolizumab - Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 2 | Withdrawn | Northwestern University | 2020-03-01 | 2023-10-10 |
Enteropathy-Associated T-Cell Lymphoma (1) · Immunoblastic Lymphadenopathy (1) · Lymphoma, T-Cell (1) · Subcutaneous panniculitis-like T-cell lymphoma (1)
Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphadenopathy (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Brentuximab Vedotin (1) · pembrolizumab (1)
United States (1)
P30CA060553 (1)